Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells-Reference-Cited by-同舟云学术

Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells

Published:2021-12 Issue: Volume:582 Page:137-143
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Lan Keng-Hsueh^ORCID,Tsai Cheng-Liang^ORCID,Chen Yu-Yi,Lee Tun-Ling,Pai Chiung-Wen,Chao Yee,Lan Keng-Li

Funder

Ministry of Science and Technology, Taiwan

Taipei Veterans General Hospital

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference19 articles.

1. Evolution of anti-HER2 therapies for cancer treatment;Parakh;Canc. Treat Rev.,2017

2. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions;Ferraro;Breast Cancer Res.,2021

3. Treatment landscape for patients with HER2-positive metastatic breast cancer: a review on emerging treatment options;Gampenrieder;Canc. Manag. Res.,2020

4. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions;Vermes;J. Antimicrob. Chemother.,2000

5. Design of an optimized scaffold for affibody molecules;Feldwisch;J. Mol. Biol.,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation;Frontiers in Immunology;2024-08-08

2. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs;Cancers;2022-09-19